← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

MindWalk Holdings Corp. (HYFT) 10-Year Financial Performance & Capital Metrics

HYFT • • Industrial / General
HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms
AboutMindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.Show more
  • Revenue $24M -2.0%
  • EBITDA -$7M +14.9%
  • Net Income -$30M -13.4%
  • EPS (Diluted) -0.90 +11.8%
  • Gross Margin 47.31% +27.7%
  • EBITDA Margin -29.6% +13.2%
  • Operating Margin -50.47% +12.2%
  • Net Margin -123.3% -15.8%
  • ROE -104.17% -80.8%
  • ROIC -26.1% -23.2%
  • Debt/Equity 0.57 +40.7%
  • Interest Coverage -1237.63 -64.9%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 96 (top 4%)
  • ✓Strong 5Y sales CAGR of 10.6%

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Shares diluted 30.2% in last year
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y10.55%
3Y7.07%
TTM14.38%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-13.21%

EPS CAGR

10Y-
5Y-
3Y-
TTM12.76%

ROCE

10Y Avg-29.5%
5Y Avg-25.08%
3Y Avg-29.54%
Latest-28.11%

Peer Comparison

Antibody Discovery Platforms
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
NAGENiagen Bioscience Inc503.58M6.3157.3619.18%16.38%28.91%2.37%0.06
BTXBlackRock Technology and Private Equity Term Trust808.8M6.9340.76-81.13%87.75%1.87%34.27%
HALOHalozyme Therapeutics, Inc.8.45B71.8220.9422.44%47.91%118.17%5.55%4.14
RPRXRoyalty Pharma plc16.97B39.7220.80-3.86%32.55%7.95%16.32%0.74
REGNRegeneron Pharmaceuticals, Inc.76.63B741.9219.358.27%32.13%14.79%4.78%0.09
GMABGenmab A/S20.85B33.852.7930.67%46.8%114.25%36.37%0.03
DNAGinkgo Bioworks Holdings, Inc.464.86M9.58-0.91-9.71%-188%-60.66%0.65
PRMEPrime Medicine, Inc.720.24M3.99-2.42-33.02%-121.95%0.27

Profit & Loss

Apr 2016Apr 2017Apr 2018Apr 2019Apr 2020Apr 2021Apr 2022Apr 2023Apr 2024Apr 2025
Sales/Revenue+02.72M5.47M11.15M14.72M17.91M19.8M21.17M24.81M24.31M
Revenue Growth %--1.01%1.04%0.32%0.22%0.11%0.07%0.17%-0.02%
Cost of Goods Sold+8231.98M6.76M13.04M15.3M6.51M10.63M13.85M15.62M12.81M
COGS % of Revenue-0.73%1.24%1.17%1.04%0.36%0.54%0.65%0.63%0.53%
Gross Profit+-823743.76K-1.29M-1.89M-576.29K11.4M9.17M7.32M9.19M11.5M
Gross Margin %-0.27%-0.24%-0.17%-0.04%0.64%0.46%0.35%0.37%0.47%
Gross Profit Growth %0.21%904.72%-2.74%-0.46%0.69%20.79%-0.2%-0.2%0.26%0.25%
Operating Expenses+33.61K2.13M3.51M4.47M3.71M5.42M26.3M36.58M23.46M23.77M
OpEx % of Revenue-0.78%0.64%0.4%0.25%0.3%1.33%1.73%0.95%0.98%
Selling, General & Admin33.61K1.45M3M3.97M3.24M13.27M18.05M18.19M19.14M19.03M
SG&A % of Revenue-0.53%0.55%0.36%0.22%0.74%0.91%0.86%0.77%0.78%
Research & Development0683.24K511.84K495.75K467.29K1.86M7.84M12.58M4.09M4.9M
R&D % of Revenue-0.25%0.09%0.04%0.03%0.1%0.4%0.59%0.16%0.2%
Other Operating Expenses00000-9.7M409.34K5.81M229.77K-163.23K
Operating Income+-34.43K-1.39M-4.8M-6.35M-4.29M-5.28M-17.13M-29.25M-14.26M-12.27M
Operating Margin %--0.51%-0.88%-0.57%-0.29%-0.3%-0.86%-1.38%-0.57%-0.5%
Operating Income Growth %0.48%-39.31%-2.46%-0.32%0.33%-0.23%-2.24%-0.71%0.51%0.14%
EBITDA+-33.61K-1.34M-4.34M-4.04M-719.03K-2.45M-13.27M-22.4M-8.46M-7.19M
EBITDA Margin %--0.49%-0.79%-0.36%-0.05%-0.14%-0.67%-1.06%-0.34%-0.3%
EBITDA Growth %0.48%-38.74%-2.25%0.07%0.82%-2.41%-4.42%-0.69%0.62%0.15%
D&A (Non-Cash Add-back)82352.36K460.41K2.31M3.57M2.84M3.85M6.85M5.8M5.08M
EBIT-34.23K-5.64M-5M-6.91M-4.81M-6.65M-16.12M-28.4M-29.03M-33.96M
Net Interest Income+-259-16.77K-10.85K-827.63K-451.46K-337.37K194K92K4K-9.91K
Interest Income0073.37K30.7K284.81K265K279K122K23K0
Interest Expense26016.77K84.22K858.32K736.27K602.37K85K30K19K9.91K
Other Income/Expense-63-4.27M-285.76K-1.41M-1.25M705.68K920.4K818.65K-14.79M-21.7M
Pretax Income+-34.49K-5.66M-5.09M-7.77M-5.54M-4.58M-16.21M-28.43M-29.05M-33.97M
Pretax Margin %--2.08%-0.93%-0.7%-0.38%-0.26%-0.82%-1.34%-1.17%-1.4%
Income Tax+0-85.22K110.27K4.88K-362K1.34M880.52K-1.22M-2.62M-4M
Effective Tax Rate %1%0.98%1.02%1%0.93%1.6%1.05%0.96%0.91%0.88%
Net Income+-34.49K-5.57M-5.2M-7.77M-5.18M-7.34M-17.09M-27.21M-26.43M-29.97M
Net Margin %--2.05%-0.95%-0.7%-0.35%-0.41%-0.86%-1.29%-1.07%-1.23%
Net Income Growth %0.45%-160.48%0.07%-0.5%0.33%-0.42%-1.33%-0.59%0.03%-0.13%
Net Income (Continuing)-34.49K-5.57M-5.2M-7.77M-5.18M-7.34M-17.09M-27.21M-26.43M-29.97M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+0.10-1.36-0.57-0.61-0.36-0.45-0.85-1.07-1.02-0.90
EPS Growth %1.91%-14.6%0.58%-0.07%0.41%-0.25%-0.89%-0.26%0.05%0.12%
EPS (Basic)0.10-1.36-0.57-0.61-0.36-0.45-0.85-1.07-1.02-0.90
Diluted Shares Outstanding2M3.96M9.11M12.54M13.63M16.47M19.69M24.9M25.64M33.38M
Basic Shares Outstanding2M3.96M9.11M12.54M13.63M16.47M19.69M24.9M25.64M33.38M
Dividend Payout Ratio----------

Balance Sheet

Apr 2016Apr 2017Apr 2018Apr 2019Apr 2020Apr 2021Apr 2022Apr 2023Apr 2024Apr 2025
Total Current Assets+1.22M3.28M4.78M9.88M7.7M48.86M37.47M16.79M11.49M18.75M
Cash & Short-Term Investments555.02K2.58M1.81M5.47M2.61M41.76M29.96M8.28M3.46M10.66M
Cash Only340.88K2.58M1.81M5.47M2.61M41.76M29.96M8.28M3.46M10.66M
Short-Term Investments214.14K000000000
Accounts Receivable450.91K469.49K2.22M1.95M3.66M3.63M3.41M3.88M4.07M4.81M
Days Sales Outstanding-62.97148.2463.990.7673.9362.8366.8759.8372.16
Inventory2.79K58.5K412.69K2.12M818.64K1.2M1.61M2.06M2.14M2.1M
Days Inventory Outstanding1.24K10.822.2859.3819.5367.5355.4654.349.9959.7
Other Current Assets209.05K61.15K0089.09K491K0536K414K0
Total Non-Current Assets+162.65K644.58K19.79M18.47M19.56M18.1M56.02M61.02M48.5M25.69M
Property, Plant & Equipment162.65K644.58K1.58M1.64M3.17M4.08M3.71M10.72M16.7M16.26M
Fixed Asset Turnover-4.22x3.46x6.80x4.65x4.39x5.34x1.97x1.49x1.49x
Goodwill004.89M8.25M7.91M7.78M19.7M19.17M7.69M8.23M
Intangible Assets004.04M8.42M8.29M6.06M32.39M30.93M23.56M1.07M
Long-Term Investments0090.4K90.4K118.9K111K142K115K62.6K91.22K
Other Non-Current Assets009.19M67.45K85.13K79K82K86K498.4K34.78K
Total Assets+1.38M3.93M24.58M28.35M27.26M66.96M93.49M77.81M59.99M44.44M
Asset Turnover-0.69x0.22x0.39x0.54x0.27x0.21x0.27x0.41x0.55x
Asset Growth %28.93%1.85%5.25%0.15%-0.04%1.46%0.4%-0.17%-0.23%-0.26%
Total Current Liabilities+385.52K836.91K4.28M7.2M7.93M6.07M9.26M5.92M8.12M9.01M
Accounts Payable100.81K664.45K2.03M1.59M1.35M1.34M3.92M2.48M4.07M5.28M
Days Payables Outstanding44.71K122.63109.6344.6332.375.43134.565.4795.16150.54
Short-Term Debt00187.81K2.79M2.12M801.5K1.31M822.83K1.14M1.34M
Deferred Revenue (Current)279.33K172.47K317.54K724.69K1000K1000K1000K720.34K01000K
Other Current Liabilities284.71K02.05M2.78M2.23M22.5K1.13M-127.17K1.35M-1.03M
Current Ratio3.16x3.92x1.12x1.37x0.97x8.05x4.05x2.84x1.41x2.08x
Quick Ratio3.15x3.85x1.02x1.08x0.87x7.85x3.87x2.49x1.15x1.85x
Cash Conversion Cycle--48.8760.978.6577.9866.02-16.2155.6914.65-18.68
Total Non-Current Liabilities+86.63K07.59M3.07M4.25M3.96M9.07M14.09M17.94M11.8M
Long-Term Debt003.59M28.72K503K1.53M0000
Capital Lease Obligations0038.98K71.32K1.13M940K468K6.15M12.12M11.55M
Deferred Tax Liabilities86.63K0882.34K1.94M1.6M1.49M8.11M7.66M5.83M250K
Other Non-Current Liabilities003.96M2.97M01.49M497K278K5.83M0
Total Liabilities472.15K836.91K11.87M10.28M12.18M10.04M18.36M20.01M26.07M20.82M
Total Debt+003.82M2.93M4.51M3.46M2.77M7.27M13.68M13.4M
Net Debt-340.88K-2.58M2.01M-2.54M1.9M-38.3M-27.2M-1.01M10.22M2.74M
Debt / Equity--0.30x0.16x0.30x0.06x0.04x0.13x0.40x0.57x
Debt / EBITDA----------
Net Debt / EBITDA----------
Interest Coverage-132.47x-82.73x-57.01x-7.40x-5.82x-8.77x-201.50x-975.11x-750.64x-1237.63x
Total Equity+908.26K3.09M12.7M18.07M15.09M56.92M75.28M57.8M33.92M23.63M
Equity Growth %5.36%2.4%3.11%0.42%-0.17%2.77%0.32%-0.23%-0.41%-0.3%
Book Value per Share0.450.781.391.441.113.463.822.321.320.71
Total Shareholders' Equity908.26K3.09M12.7M18.07M15.09M56.92M75.28M57.8M33.92M23.63M
Common Stock2327.46M20.46M32.7M34.09M80.1M114.56M117.47M119.77M136.37M
Retained Earnings907.93K-4.57M-9.74M-17.48M-22.48M-29.82M-46.53M-73.09M-100.27M-128.79M
Treasury Stock0000000000
Accumulated OCI-686.61K-737.22K277.09K-228.06K-300.22K-687K-2.48M2.63M2.02M3.22M
Minority Interest0000000000

Cash Flow

Apr 2016Apr 2017Apr 2018Apr 2019Apr 2020Apr 2021Apr 2022Apr 2023Apr 2024Apr 2025
Cash from Operations+284.09K-721.65K-3.42M-3.21M-1.39M-600K-9.92M-19.83M-4.25M-6.41M
Operating CF Margin %--0.27%-0.62%-0.29%-0.09%-0.03%-0.5%-0.94%-0.17%-0.26%
Operating CF Growth %8.87%-3.54%-3.73%0.06%0.57%0.57%-15.54%-1%0.79%-0.51%
Net Income151.03K-5.38M-5.17M-7.62M-4.95M-7.34M-16.71M-26.56M-27.18M-30.23M
Depreciation & Amortization41.88K50.61K458.08K2.26M3.41M3.71M3.77M6.68M5.74M5.12M
Stock-Based Compensation0198.03K1.22M1.11M739.01K2.75M3.08M1.94M1.53M445K
Deferred Taxes0-82.38K63.39K-578.97K-455.16K-83K-336K-926K-1.77M-3.94M
Other Non-Cash Items19.34K4.12M205.19K1.03M982.13K1.38M-310K2.3M15.68M21.92M
Working Capital Changes71.83K380.69K-193.38K580.64K-1.12M-1.02M582K-3.28M1.76M276.99K
Change in Receivables-74.9K-46.8K-284.95K102.11K-933.28K-439K163K-561K-241K-391.8K
Change in Inventory0-58.5K-27.94K289.52K-23.39K-316K-501K-185K-102K99.03K
Change in Payables0592.86K482.99K-421.67K172K-73K781K-1.55M727.98K593.45K
Cash from Investing+-81.59K-174.61K-7.17M-2.2M-1.58M-2.46M-5.21M-1.97M-1.56M-799K
Capital Expenditures-17.48K-530.75K-345.49K-645.06K-575.64K-1.43M-1.26M-1.5M-1.4M-799K
CapEx % of Revenue-0.2%0.06%0.06%0.04%0.08%0.06%0.07%0.06%0.03%
Acquisitions----------
Investments----------
Other Investing-64.11K214.14K0000-259K40K-141K0
Cash from Financing+-91.91K3.17M9.8M9.35M174.7K43.38M2.88M-621K1.02M14.89M
Debt Issued (Net)----------
Equity Issued (Net)----------
Dividends Paid-65K-90K00000000
Share Repurchases----------
Other Financing0-1.15M-29.67K-288.5K7010-5K0612.26K0
Net Change in Cash----------
Free Cash Flow+266.61K-1.25M-3.76M-3.85M-1.97M-2.03M-11.18M-21.33M-5.64M-7.21M
FCF Margin %--0.46%-0.69%-0.35%-0.13%-0.11%-0.56%-1.01%-0.23%-0.3%
FCF Growth %5.73%-5.7%-2%-0.02%0.49%-0.03%-4.51%-0.91%0.74%-0.28%
FCF per Share0.13-0.32-0.41-0.31-0.14-0.12-0.57-0.86-0.22-0.22
FCF Conversion (FCF/Net Income)-8.24x0.13x0.66x0.41x0.27x0.08x0.58x0.73x0.16x0.21x
Interest Paid00533371.26K301K120K38K263K00
Taxes Paid00152.17K415.14K238K1.1M1.19M591K02K

Key Ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-9.86%-278.48%-65.81%-50.52%-31.25%-20.39%-25.85%-40.9%-57.63%-104.17%
Return on Invested Capital (ROIC)-12.04%-192.58%-47.29%-31.52%-19.78%-22.26%-38.51%-41.84%-21.2%-26.1%
Gross Margin-27.33%-23.63%-16.92%-3.92%63.67%46.32%34.59%37.05%47.31%
Net Margin--204.67%-95.03%-69.72%-35.19%-40.98%-86.29%-128.53%-106.51%-123.3%
Debt / Equity--0.30x0.16x0.30x0.06x0.04x0.13x0.40x0.57x
Interest Coverage-132.47x-82.73x-57.01x-7.40x-5.82x-8.77x-201.50x-975.11x-750.64x-1237.63x
FCF Conversion-8.24x0.13x0.66x0.41x0.27x0.08x0.58x0.73x0.16x0.21x
Revenue Growth--100.96%103.86%32.03%21.69%10.56%6.92%17.19%-2.03%

Revenue by Segment

2022202320242025
Project Revenue17.36M18.68M22.23M22.18M
Project Revenue Growth-7.61%19.05%-0.27%
Product Sales1.65M1.75M2.04M2.11M
Product Sales Growth-5.75%16.49%3.54%

Revenue by Geography

2022202320242025
UNITED STATES6.82M9.37M12.56M12.61M
UNITED STATES Growth-37.40%34.07%0.46%
Europe9.43M9.45M10.87M10.18M
Europe Growth-0.22%14.99%-6.34%
AUSTRALIA1.54M630K482K896K
AUSTRALIA Growth--59.09%-23.49%85.89%
All Other Countries1.01M602K224K598K
All Other Countries Growth--40.22%-62.79%166.96%
CANADA572K618K389K234K
CANADA Growth-8.04%-37.06%-39.85%

Frequently Asked Questions

Growth & Financials

MindWalk Holdings Corp. (HYFT) reported $20.5M in revenue for fiscal year 2025.

MindWalk Holdings Corp. (HYFT) saw revenue decline by 2.0% over the past year.

MindWalk Holdings Corp. (HYFT) reported a net loss of $30.6M for fiscal year 2025.

Dividend & Returns

MindWalk Holdings Corp. (HYFT) has a return on equity (ROE) of -104.2%. Negative ROE indicates the company is unprofitable.

MindWalk Holdings Corp. (HYFT) had negative free cash flow of $10.3M in fiscal year 2025, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.